Semaglutide Reduces BMI Category for Adolescents With Obesity
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 7, 2023 -- For adolescents with obesity, semaglutide is effective for reducing body mass index (BMI) category, according to a study published online May 17 in Obesity.
Aaron S. Kelly, Ph.D., from the University of Minnesota Medical School in Minneapolis, and colleagues examined how improvement in BMI with the glucagon-like peptide-1 receptor agonist semaglutide translated into changes in BMI category in a post hoc analysis of the phase-3a STEP TEENS trial. Adolescents with obesity received once-weekly subcutaneous semaglutide 2.4 mg or placebo plus lifestyle intervention.
The researchers found that in the overall population, 44.9 percent of participants receiving semaglutide and 12.1 percent receiving placebo achieved the normal weight or overweight BMI category at week 68 (odds ratio, 22.7). There was a decrease from 37.3 to 13.6 percent in the proportion of semaglutide-treated participants in obesity class III, whereas an increase was seen in placebo-treated participants. For achieving an improvement of one or more BMI category, the odds were significantly greater with semaglutide versus placebo (odds ratio, 23.5). In addition, 73.7 versus 19.0 percent of participants receiving semaglutide versus placebo had an improvement of one or more BMI category.
"These results underscore the high degree of clinical effectiveness of semaglutide in adolescents with obesity," Kelly said in a statement. "In a practical sense, we see that semaglutide reduced weight to a level below what is defined as clinical obesity in nearly 50 percent of the teens in our trial, which is historically unprecedented with treatments other than bariatric surgery."
Several authors disclosed ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults
FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...
Weight Navigation Program Boosts Use of Weight Management Treatments
FRIDAY, May 31, 2024 -- A primary care-based weight navigation program (WNP) is feasible and associated with greater use of weight management treatments (WMT) and weight loss...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.